MARKET

XTLB

XTLB

X T L Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.070
-0.041
-1.93%
Closed 16:00 09/18 EDT
OPEN
2.060
PREV CLOSE
2.111
HIGH
2.120
LOW
2.050
VOLUME
9.13K
TURNOVER
--
52 WEEK HIGH
2.350
52 WEEK LOW
0.6250
MARKET CAP
10.64M
P/E (TTM)
-3.8333
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
Intra-Cellular Therapies, Trillium Therapeutics leads gainers, Co-Diagnostics, Applied Genetic Technologies among losers
Gainers: Intra-Cellular Therapies (ITCI) +65%, Trillium Therapeutics (TRIL) +36%, Amryt Pharma (AMYT) +25%, BeyondSpring (BYSI) +18%, XTL Biopharmaceuticals (XTLB) +17%.Losers: Co-Diagnostics (CODX) -17%, Applied Genetic Technologies (AGTC) -16%, SCWorx (WORX) -10%, Innate Pharma (IPHA) -7%, PolarityTE (PTE) -5%.
Seekingalpha · 09/09 15:07
KODK, MARA, NOV and AUDC among midday movers
Seeking Alpha · 07/28 16:41
Microcaps mostly among midday movers
Seeking Alpha - Article · 06/16 17:08
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4)
Benzinga · 12/05/2019 12:14
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20)
Benzinga · 11/21/2019 12:22
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14)
Benzinga · 11/15/2019 12:08
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12)
Benzinga · 11/13/2019 12:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
EPS
Institutional Holdings
Institutions: 5
Institutional Holdings: 469.10K
% Owned: 9.12%
Shares Outstanding: 5.14M
TypeInstitutionsShares
Increased
1
1.90K
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Director
Shlomo Shalev Spokone
Chairman/Director
Shlomo Shalev
Chief Executive Officer
Joshua Levine
Deputy Chief Executive Officer/Chief Financial Officer
Ronen Twito
Other
Moshe Mittelman
Director
Daphna Paran
Director
Alexander Rabinovich
Director
Alexander Rabinovitch
Non-Executive Director
Dafna Cohen
Non-Executive Director
Jaron Diament
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XTLB
XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of X T L Biopharmaceuticals Ltd (ADR) stock information, including NASDAQ:XTLB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XTLB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XTLB stock methods without spending real money on the virtual paper trading platform.